MPS在三个r中的使用和监管应用:来自开发商对利益相关者责任的观点。

IF 2.4 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Megan R LaFollette, Szczepan W Baran, J Lowry Curley, Anne M Dickinson, Trivia Frazier, Nina Hobi, Ming-I Huang, Victoria Hutter, Benoît G C Maisonneuve, Graham A Marsh, Rhamiya Mahendran, Iris Müller, Xiaohua Qian, Dharaminder Singh, William R Thelin, Jelena Vukasinovic, Pelin L Candarlioglu, Clive S Roper
{"title":"MPS在三个r中的使用和监管应用:来自开发商对利益相关者责任的观点。","authors":"Megan R LaFollette, Szczepan W Baran, J Lowry Curley, Anne M Dickinson, Trivia Frazier, Nina Hobi, Ming-I Huang, Victoria Hutter, Benoît G C Maisonneuve, Graham A Marsh, Rhamiya Mahendran, Iris Müller, Xiaohua Qian, Dharaminder Singh, William R Thelin, Jelena Vukasinovic, Pelin L Candarlioglu, Clive S Roper","doi":"10.1177/02611929241310566","DOIUrl":null,"url":null,"abstract":"<p><p>Increasing the use of microphysiological systems (MPS) in Three Rs and regulatory applications is a nuanced but important goal, which would also help increase their scientific impact. There are three distinct and important stakeholder groups that each play a unique role in expediting the use of MPS for regulatory purpose - namely, commercial MPS developers, end-users and regulators. Additionally, non-profit organisations, such as the 3Rs Collaborative (3RsC), can help coordinate these efforts. This paper introduces the MPS Initiative, as organised by the 3RsC, and clarifies the potential for MPS to benefit all Three Rs. Key differences in the use of MPS-derived data for regulatory evidence of efficacy versus safety, and for various other contexts of use, are discussed. Finally, the results are presented from a survey of primarily commercial MPS developers, that collected their views on the realistic responsibilities of each stakeholder group. The results also highlight their key perspectives on the use of MPS, in the context of Three Rs and regulatory applications.</p>","PeriodicalId":55577,"journal":{"name":"Atla-Alternatives To Laboratory Animals","volume":"53 1","pages":"26-41"},"PeriodicalIF":2.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Use of MPS in Three Rs and Regulatory Applications: Perspectives From Developers on Stakeholder Responsibilities.\",\"authors\":\"Megan R LaFollette, Szczepan W Baran, J Lowry Curley, Anne M Dickinson, Trivia Frazier, Nina Hobi, Ming-I Huang, Victoria Hutter, Benoît G C Maisonneuve, Graham A Marsh, Rhamiya Mahendran, Iris Müller, Xiaohua Qian, Dharaminder Singh, William R Thelin, Jelena Vukasinovic, Pelin L Candarlioglu, Clive S Roper\",\"doi\":\"10.1177/02611929241310566\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Increasing the use of microphysiological systems (MPS) in Three Rs and regulatory applications is a nuanced but important goal, which would also help increase their scientific impact. There are three distinct and important stakeholder groups that each play a unique role in expediting the use of MPS for regulatory purpose - namely, commercial MPS developers, end-users and regulators. Additionally, non-profit organisations, such as the 3Rs Collaborative (3RsC), can help coordinate these efforts. This paper introduces the MPS Initiative, as organised by the 3RsC, and clarifies the potential for MPS to benefit all Three Rs. Key differences in the use of MPS-derived data for regulatory evidence of efficacy versus safety, and for various other contexts of use, are discussed. Finally, the results are presented from a survey of primarily commercial MPS developers, that collected their views on the realistic responsibilities of each stakeholder group. The results also highlight their key perspectives on the use of MPS, in the context of Three Rs and regulatory applications.</p>\",\"PeriodicalId\":55577,\"journal\":{\"name\":\"Atla-Alternatives To Laboratory Animals\",\"volume\":\"53 1\",\"pages\":\"26-41\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atla-Alternatives To Laboratory Animals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/02611929241310566\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atla-Alternatives To Laboratory Animals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02611929241310566","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

在3r和监管应用中增加微生理系统(MPS)的使用是一个微妙但重要的目标,这也将有助于提高它们的科学影响。有三个不同而重要的利益相关者群体,每个群体在加速MPS用于监管目的方面都发挥着独特的作用——即商业MPS开发商、最终用户和监管机构。此外,非营利组织,如3r协作组织(3RsC),可以帮助协调这些努力。本文介绍了由3RsC组织的MPS倡议,并阐明了MPS对所有三个Rs有利的潜力。讨论了将MPS衍生数据用于有效性与安全性的监管证据以及各种其他使用情况的关键差异。最后,结果来自于对主要商业MPS开发者的调查,收集了他们对每个利益相关者群体的现实责任的看法。研究结果还强调了他们在3r和监管应用的背景下对MPS使用的关键观点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Use of MPS in Three Rs and Regulatory Applications: Perspectives From Developers on Stakeholder Responsibilities.

Increasing the use of microphysiological systems (MPS) in Three Rs and regulatory applications is a nuanced but important goal, which would also help increase their scientific impact. There are three distinct and important stakeholder groups that each play a unique role in expediting the use of MPS for regulatory purpose - namely, commercial MPS developers, end-users and regulators. Additionally, non-profit organisations, such as the 3Rs Collaborative (3RsC), can help coordinate these efforts. This paper introduces the MPS Initiative, as organised by the 3RsC, and clarifies the potential for MPS to benefit all Three Rs. Key differences in the use of MPS-derived data for regulatory evidence of efficacy versus safety, and for various other contexts of use, are discussed. Finally, the results are presented from a survey of primarily commercial MPS developers, that collected their views on the realistic responsibilities of each stakeholder group. The results also highlight their key perspectives on the use of MPS, in the context of Three Rs and regulatory applications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.80
自引率
3.70%
发文量
60
审稿时长
>18 weeks
期刊介绍: Alternatives to Laboratory Animals (ATLA) is a peer-reviewed journal, intended to cover all aspects of the development, validation, implementation and use of alternatives to laboratory animals in biomedical research and toxicity testing. In addition to the replacement of animals, it also covers work that aims to reduce the number of animals used and refine the in vivo experiments that are still carried out.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信